Introduction
Large granular lymphocytes (LGLs) represent 10% to 15% of total peripheral blood mononuclear cells in normal adults [1] . The majority of normal LGLs (85%) are derived from natural killer (NK)-cell (CD3 -) lineage and a minority (15%) from T-cell (CD3 + ) lineage. T-cell LGLs are postthymic, antigen-primed, cytotoxic CD8 + T lymphocytes. NK-cell LGLs belong to the innate immune system with the capability of non-major histocompatibility complex (MHC)-restricted cytotoxicity [1] . The term
LGL leukemia was first introduced in 1985 to describe a clonal disorder involving blood, marrow, and spleen [2] . In 1993, we proposed two LGL disorders based on either T-cell or NK-cell lineage; these were subsequently accepted by all pathology classification systems [1] . The World Health Organization (WHO) classification of lymphoid malignancies includes indolent T-cell LGL leukemia and aggressive NK-cell leukemia as two separate entities among T/NK-cell lymphomas/leukemias [3] . Because aggressive T-cell LGL leukemia is rare and chronic NK-cell leukemia is difficult to separate from reactive NK-cell lymphocytosis (because of a lack of clonality markers), these two diseases did not receive separate status in the WHO classification [4] .
T-cell LGL Leukemia

Epidemiology
Indolent T-cell LGL leukemia is the most frequent LGL disorder in Western countries, accounting for 85% of all cases [1]. The median age at diagnosis is 60 years; the sexes are affected equally.
Etiopathogenesis
The etiology of T-cell LGL leukemia has not been entirely elucidated, but chronic antigenic stimulation with exogenous antigens such as human T-cell lymphotrophic virus (HTLV) or putative endogenous autoantigens may be responsible for inducing the activation and clonal expansion of effector CD8 + LGLs [5] . Dysregulation of several intracellular signaling pathways, including FAS/FAS-L, PI3K-AKT, and extracellular signal-regulated kinase (ERK), has been implicated in inhibition of apoptosis of leukemic LGLs in in vitro studies [6,7•,8•] .
Clinical manifestations
Although most cases of T-cell LGL leukemia have an indolent behavior, approximately 60% of patients will become symptomatic during the course of their disease [1, 4] . Most patients present with an absolute LGL count greater than 2.0 × 10 9 /L (normal range 0.2-0.4 × 10 9 /L) [1] .
Cytopenias
Of patients with T-cell LGL leukemia, 80% will develop neutropenia and approximately 45% will experience severe neutropenia as defined by an absolute neutrophil count below 0.5 × 10 9 /L [1, 9] . Recurrent bacterial infections secondary to neutropenia are common initial clinical manifestations [10] . Most of these infections are mucocutaneous. The development of opportunistic infections is not characteristic of T-cell LGL leukemia [1] . Anemia, caused by various pathogenic mechanisms, has been reported in 48% of patients [4, 9] . In a single institutional study, T-cell LGL leukemia was found to be the most common cause of pure red cell aplasia [11] . Thrombocytopenia is detected in 20% of patients, and splenomegaly is detected in 20% to 50% [4, 9] .
Autoimmune disorders
Autoimmune disorders such as rheumatoid arthritis occur in 25% to 35% of patients with T-cell LGL leukemia [1, 4] . The presence of rheumatoid arthritis, neutropenia, and splenomegaly (known as Felty syndrome) can be difficult to distinguish from T-cell LGL leukemia associated with rheumatoid arthritis [12] . Patients with both conditions have a higher frequency of the HLA-DR4 haplotype than the general population, suggesting a common immunologic mechanism [4, 9] .
Association with bone marrow failure disorders
Concurrent manifestation of indolent T-cell LGL leukemia and various disorders of bone marrow failure including myelodysplastic syndromes, aplastic anemia, and paroxysmal nocturnal hemoglobinuria have also been described [13, 14] . Several reports have suggested that clonal T cells might be derived from pluripotent hematopoietic stem cells in patients with myelodysplastic syndromes [15] . On the other hand, a clonal expansion of T-cell LGLs could be explained with chronic stimulation by an abnormal autoantigen expressed by MDS clone in bone marrow (autoimmune hypothesis) [16] .
Diagnosis
The diagnosis of T-cell LGL leukemia is based upon the presence of an LGL lymphocytosis, characteristic immunophenotype, and confirmation of clonality using T-cell receptor (TCR) and rearrangement studies (Fig. 1) [1, 4, 17] .
Cytology
Morphologically, LGLs are medium to large cells containing abundant cytoplasm, coarse azurophilic granules, and eccentric nuclei (Fig. 2) [1, 4] . Examination of the marrow will demonstrate clonal populations of LGLs in an interstitial pattern [1, 4] . The extent of marrow involvement is highly variable and does not correlate with the severity of symptoms or the degree of cytopenias [4, 9] . T-cell LGL leukemic cells typically coexpress CD3 + CD8 + CD57 + markers [1, 4] . The majority of patients with T-cell LGL leukemia express the type of T-cell receptor (TCR ). Rare immunophenotypic variants such as CD3 + CD4 + CD8 + CD57 + TCR , CD3 + CD4 -CD8 -CD57 + TCR , and CD3 + CD4 -CD8 -CD57 + TCR have also been described [3, 4] 
Immunophenotype and genotype
